All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Affymax Inc. raised $60 million in a Series D financing to push along its Phase II candidate Hematide for anemia, which is expected to be studied in four separate trials by late fall. (BioWorld Today)